Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N4WB
|
|||
| Former ID |
DNC004415
|
|||
| Drug Name |
SB-415286
|
|||
| Synonyms |
SB 415286; 264218-23-7; SB-415286; SB415286; 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione; CHEMBL322970; 3-(3-chloro-4-hydroxyanilino)-4-(2-nitrophenyl)pyrrole-2,5-dione; 3-[(3-chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 1H-Pyrrol-2,5-dione, 3-((3-chloro-4-hydroxyphenyl)amino)-4-(2-nitrophenyl)-; SMR000568415; SR-01000075855
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H10ClN3O5
|
|||
| Canonical SMILES |
C1=CC=C(C(=C1)C2=C(C(=O)NC2=O)NC3=CC(=C(C=C3)O)Cl)[N+](=O)[O-]
|
|||
| InChI |
1S/C16H10ClN3O5/c17-10-7-8(5-6-12(10)21)18-14-13(15(22)19-16(14)23)9-3-1-2-4-11(9)20(24)25/h1-7,21H,(H2,18,19,22,23)
|
|||
| InChIKey |
PQCXVIPXISBFPN-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 264218-23-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
6173380, 8387211, 11109050, 11111800, 11114154, 11121581, 11122061, 11362650, 11365212, 11367774, 11370571, 11370572, 11373375, 11375936, 14828233, 17405044, 24278412, 26752224, 35496324, 47498109, 47498110, 47719265, 48317018, 49674511, 50069834, 50104914, 50104915, 53777587, 53789039, 56463775, 57356843, 71745855, 78669802, 85231226, 85788271, 90341705, 91722320, 92303814, 92309932, 99300846, 99302364, 103336904, 104022026, 112770517, 121264554, 121361147, 124659173, 124801122, 124881441, 124881442
|
|||
| ChEBI ID |
CHEBI:91107
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8019). | |||
| REF 2 | Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71. | |||
| REF 3 | 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg Med Chem Lett. 2001 Mar 12;11(5):635-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.